Advertisement
"This new round of funding will allow the company to continue on itssignificant growth trajectory by introducing new and important treatmentoptions for children. We are grateful to the company's investors forrecognizing the significant value that Arbor has created as an emerging leaderin pediatric pharmaceuticals. Arbor is well positioned to continue tointroduce important and novel pediatric treatment options and furtherestablish Arbor as a leader in the growing pediatric pharmaceuticals market,"says Jarrett Disbrow, President & CEO of Arbor.
Advertisement
In addition to completing the Series A financing Arbor has recentlydeployed a specialty sales force focused on promoting the company's productsto pediatricians across the United States. The company also has a promotionalagreement with a partner company to promote Arbor's products in severalmarkets. Arbor's products are now being promoted in more than 25 major U.S.metropolitan areas. The company plans to expand its sales force in the comingmonths.
About Arbor Pharmaceuticals
Arbor Pharmaceuticals is a Raleigh, North Carolina-based specialtypharmaceutical company focused exclusively on the growing pediatric market.Arbor actively licenses, develops and commercializes pediatric productsinitially focused on nonantibiotic products for the treatment of various earinfections and currently markets two patented products, ZINOTIC(R) andNEOTIC(R). The company intends to become the leading pediatric pharmaceuticalcompany by developing and commercializing a robust pipeline of late-stageproducts for common pediatric conditions. Arbor will launch a novel treatmentoption for recurrent middle ear infections in early 2009.
To learn more about Arbor Pharmaceuticals, visit www.arborpharma.com orsend email inquiries to [email protected].
SOURCE Arbor Pharmaceuticals
